|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,240.00 ILa | -0.71% |
|
+2.47% | -0.88% |
| 06-01 | Kamada Announces FDA Approval of Its New In-House Rabies Virus Neutralization Testing Laboratory | CI |
| 05-13 | Kamada Ltd., Q1 2026 Earnings Call, May 13, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 434M | - | - | - | ||
| 66.11B | |||||
| 55.3B | |||||
| 42.44B | |||||
| 41.28B | - | ||||
| 30.78B |
- Stock Market
- Stocks
- KMDA Stock
- Charts Kamada Ltd.
- Sector Chart
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
